insights_auto
Why is DCTH up 3.67%?
Dive Deeperchevron_right
DCTH:NASDAQ
Delcath Systems Inc
$15.68
arrow_upward
+3.67%(+0.56) 1D
Oct 5, 1:42:21 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DCTH...
Open
$15.18
High
$15.80
Low
$15.06
Mkt. cap
544.25M
Avg. vol.
380.08K
Volume
113.85K
P/E ratio
2,567.10
52-wk high
$17.42
52-wk low
$8.12
EPS
$0.01
Beta
0.60
Shares outstanding
34.70M
No. of employees
156
Open
$15.18
High
$15.80
Low
$15.06
Mkt. cap
544.25M
Avg. vol.
380.08K
Volume
113.85K
P/E ratio
2,567.10
52-wk high
$17.42
52-wk low
$8.12
EPS
$0.01
Beta
0.60
Shares outstanding
34.70M
No. of employees
156
News stories
From web sources and news partners
sUAS News
·
38 minutes ago
Powerus (Nasdaq: PUSA) Awarded $82 Million Order for Counter-Unmanned Aerial Systems
Fortune
·
19 minutes ago
NYSE owner and crypto exchange OKX seek SEC clearance for tokenized U.S. stock trading
Simply Wall Street
·
8 minutes ago
3 Large Cap Tech Stocks Resetting After The Weak US Jobs Report
Seeking Alpha
·
1 hour ago
S&P 500 nears record high despite the struggling underlining breadth
Profile
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
About Delcath Systems Inc
CEOGerard Michel
Employees156
Founded1988
HeadquartersQueensbury, New York, United States
SectorMedical device
Websitedelcath.com